Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,837,699

« Back to Dashboard
Patent 5,837,699 protects NASONEX and is included in one NDA. There has been one Paragraph IV challenge on Nasonex.

Protection for NASONEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty patent family members in twenty-six countries.

Summary for Patent: 5,837,699

Title: Use of mometasone furoate for treating upper airway passage diseases
Abstract:The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s): Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:08/821,135
Patent Claim Types:
see list of patent claims
Use; Dosage form; Device;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
NASONEX
mometasone furoate monohydrate
SPRAY, METERED;NASAL020762-001Oct 1, 1997RXYes5,837,699*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,837,699

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,677,322 Use of mometasone furoate for treating airway passage and lung diseases<disabled in preview>
6,723,713 Use of mometasone furoate for treating upper airway diseases<disabled in preview>
6,956,030 Use of mometasone furoate for treating upper airway diseases<disabled in preview>
6,677,323 Use of mometasone furoate for treating airway passage and lung diseases<disabled in preview>
6,365,581 Use of mometasone furoate for treating airway passage and lung diseases<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,837,699

Country Document Number Publication Date
Finland122395Dec 30, 2011
Israel112459Mar 30, 1995
Germany69526425May 23, 2002
China100358528Jan 02, 2008
Austria525075Oct 15, 2011
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc